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cysteinyl leukotriene receptor antagonist, for the treatment of ischemia/reperfusion (I/R) injury of the
heart has been proposed in a few studies. However, the effects of zileuton and montelukast on I/R-
induced arrhythmias have not been determined.
Objective: We assessed the possible protective effects of zileuton and montelukast against I/R-induced
arrhythmias.
Methods: Forty-ﬁve male Wistar albino rats were divided into 5 groups, each containing 9 rats. Group 1:
control, Groups 2 and 3: rats treated with montelukast (10 and 30 mg/kg IP); and Groups 4 and 5: rats
treated with zileuton (1 and 3 mg/kg IV) 15 minutes before the induction of ischemia. Ischemia and
reperfusion were induced by occluding the left main coronary artery of anesthetized rats for 6 minutes
followed by reopening the artery for 6 minutes.
Results: Both doses of zileuton decreased the mean [SE] arrhythmia score (zileuton 1 mg/kg: 1.4 [0.8];
zileuton 3 mg/kg: 1.3 [0.5] vs control: 2.9 [0.3]; P o 0.05), the duration of ventricular tachycardia, and
the total length of arrhythmias, but montelukast was not effective to decrease the ventricular
arrhythmias during the 6 minutes of reperfusion.
Conclusions: The results indicate for the ﬁrst time that zileuton exerts an antiarrhythmic effect at
different doses and that montelukast is not effective against I/R-induced arrhythmias. These results
indicate that zileuton may be a candidate for drug treatment of I/R-induced arrhythmias.
& 2013. The Author. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
The initiation of reperfusion by thrombolysis or coronary
angioplasty is a standard treatment for acute myocardial infarc-
tion.1 Although the reinstitution of blood ﬂow to the previously
ischemic myocardium is the only way to save the myocardium
from eventual necrosis, reperfusion often exacerbates myocardial
damage and leads to life-threatening ventricular arrhythmias.2 The
mechanisms mediating ischemia/reperfusion (I/R)-induced
arrhythmias are not well deﬁned. However, oxidative stress,
activated neutrophils, and calcium overload are considered the
major factors associated with I/R-induced arrhythmias.3–6
Leukotrienes (LTs) are eicosanoids that are generated from
arachidonic acid by 5-lipoxygenase (5-LO) via biochemicalInc.
Biology Department, Bülent
Open access under CC BY-NC-ND licenpathways.7 LTs not only increase the severity of the inﬂammatory
response but are also produced after cardiac injury; the level of
LTB4 in particular is increased in rat myocardium after experi-
mental myocardial infarction, and in patients with cardiac ische-
mia.8,9 LTs induce the recruitment and activation of neutrophils
and increase vascular permeability. The activated neutrophils
transmigrate into ischemic tissue and release reactive oxygen
species, proteases, elastase, myeloperoxidase, and various other
mediators, all of which exacerbate inﬂammation and contribute to
tissue injury.10
Zileuton is a selective inhibitor of 5-LO, and montelukast is
a cysteinyl-LT (Cys-LT) receptor antogonist. Both compounds are
currently being used to treat patients with asthma.11 Both com-
pounds have been shown to decrease the severity of I/R injury in
various organs.12–16 A recent clinical study17 suggested that the
use of montelukast decreases the risk for myocardial infarction
and ischemic stroke. Only a few experimental studies have focused
on the cardioprotective effects of zileuton and montelukast.
Montelukast was found to be protective against isoproterenol-
induced myocardial necrosis due to its ability to inhibit LT-induced
inﬂammatuary responses.18 Zileuton has also been shown tose.
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Figure 1. Original electrocardiogram and blood pressure recordings, from (A) a control anesthetized rat, (B) a zileuton 1 mg/kg treated rat, (C) a zileuton 3 mg/kg treated rat,
(D) a montelukast 10 mg/kg treated rat, and (E) a montelukast 30 mg/kg treated rat. BP ¼ blood pressure; ECG ¼ electrocardiogram; single ¼ single extrasystole; ST ¼ ST
segment elevation; VF ¼ ventricular ﬁbrillation; VT ¼ ventricular tachycardia.
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icity by activating protein kinase C.19
Because both zileuton and montelukast may have anti-
inﬂamatory and antioxidant activities,16,18 they may also decrease
the duration of I/R-induced arrhythmias. To the best of this
author’s knowledge, the effects of zileuton and montelukast on
I/R-induced arrhythmias have not been studied previously. There-
fore, I aimed to investigate the possible antiarrhythmic effects of
zileuton and montelukast.Materials And Methods
Animals
A total of 45 male Wistar albino rats (5–6 months old weighing
between 300 and 450 g) were used in the experiments. Animals
were housed in individual cages in an animal room at a temper-
ature of 22˚C (73˚C) with 12-hour light/dark cycle and with free
access to standart pellet food and water ad libitum. All experi-
ments were performed in adherence to all of the guiding princi-
ples in the care and use of animals, together with the
recommendation from the Declaration of Helsinki, and were
approved by the Committee on Animal Research at Bülent Ecevit
University, Zonguldak, Turkey.Surgical procedures and hemodynamic measurements
Fundamental surgical procedures used in the study were
described before by Bozdogan et al.20 Brieﬂy, animals were
anaesthetized with thiopental sodium (85 mg/kg IP in a volume
of 2 mL/kg) (Abbott, İstanbul, Turkey) and tracheotomy was used
for artiﬁcial respiration. The left carotid artery was cannulated
with polyethylene tubing (0.58 mm  0.96 mm; Harvard Appa-
ratus, Boston, Massachusetts) to record the arterial blood pressure
with a blood pressure transducer (SS 13 L; Biopac Systems, Goleta,
California). A standard limb lead I electrocardiogram (ECG) was
recorded using subcutaneous needle electrodes. The chest was
opened by left thoracotomy followed by sectioning of the fourth
and ﬁfth ribs. Artiﬁcial respiration was started immediately with
room air using a volume of 1.5 mL/100 g body weight at a rate of
60 strokes/min to maintain carbon dioxide partial pressure at 18 to
24 mm Hg, partial oxygen pressure at 100 to 130 mm Hg, and pH
at 7.4 (SAR 830; IITC Life Science, Woodland Hills, California).After the pericardium was incised, the heart was eased out of
the chest by gentle pressure on the rib cage. A 5/0 silk suture was
placed around the arterial descendant branch of the left coronary
artery approximately 2 mm from its origin. The heart was placed
back into the chest cavity, attention was paid to proper reinﬂation
of the lungs. The animal was allowed to recover for a stabilization
period of 5 minutes. Any animal having arrhythmias or a sustained
decrease in mean arterial blood pressure (MABP) below 70 mm Hg
before ligation was discarded. A total of 4 animals were excluded
from the evaluation on the basis of these criteria. After stabiliza-
tion of blood pressure and heart rate (HR), coronary artery
occlusion was applied for 6 minutes by tying a knot in the
coronary artery vessel by making a bowknot. Then the silk was
pulled through the bowknot so this knot was untied to permit
reperfusion for 6 minutes.
At the termination of the experiment, heparin (500 IU/kg) was
given intravenously, and the heart was excised. The left coronary
artery was retightened, and the heart was ﬁrst perfused through
the aorta with 10 mL isotonic sodium chloride solution, followed
by 2 mL 96% ethanol for the demarcation of the occluded and
nonoccluded myocardium.20 The nonperfused area that remained
red colored (ischemic risk zone) was cut along the epicardially
visible border zone from the well-perfused area that seemed white
in color (nonischemic myocardium mass). The wet weight of the
ischemic risk zone and the total wet weight of ischemic risk zone
and nonischemic myocardium mass were measured. The ischemic
risk zone was expressed as the percentage of the total weight of
the myocardium.
Successful occlusion of the coronary artery was judged visually
by the development of pallor of the exposed myocardium, ST-
segment elevation, increased R wave amplitude on ECG, decre-
ment in MABP, and by the perfusion proved that the ligature was
at an adequate place (ischemic risk zone must be 440%), whereas
successful reperfusion was judged by the reversal of ischemia-
induced ST-segment changes and the recovery of MABP. A total of
8 animals were excluded from the evaluation on the basis of these
criteria.
Recording and arrhythmia analysis
ECG and arterial blood pressure were continuously monitored
throughout the I/R periods (Figure 1) and data subsequently
analysed using data acquisition system (MP35, Biopc System). HR
and MABP were derived from these recordings immediately before
the ligation, at 1 and 5 minutes of ligation, and at 5 minutes of
Table I
Mean [SE] arterial blood pressure (MABP) and heart rate (HR) during 6 minutes of
ischemia and reperfusion.
Time Control
Zileuton
(1 mg/kg)
Zileuton
(3 mg/kg)
Montelukast
(10 mg/kg)
Montelukast
(30 mg/kg)
MABP (mm Hg)
0 (Basal) 82 [3] 84 [3] 95 [4] 96 [7] 80 [4]
1 (Ligation
1 min)
57 [6]* 52 [7]* 73 [7]* 75 [10]* 62 [5]*
5 (Ligation
5 min)
53 [6]* 58 [10]* 90 [6] 79 [10]* 60 [7]*
11 (Reperfusion
5 min)
83 [5] 86 [4] 94 [7] 95 [10] 70 [4]
HR
0 (Basal) 393 [20] 372 [18] 395 [8] 400 [18] 398 [14]
1 (Ligation
1 min)
390 [25] 368 [22] 387 [7] 404 [20] 389 [12]
5 (Ligation
5 min)
401 [21] 387 [17] 384 [12] 400 [18] 401 [18]
11 (Reperfusion
5 min)
404 [10] 387 [17] 394 [10] 390 [19] 390 [16]
nP o 0.05 versus basal values.
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deﬁned by following guidelines of the Lambeth Conventions21 as
ventricular tachycardia (VT); ventricular ﬁbrillation (VF); and other
types of arrhythmias, including single extrasystoles, bigeminy, and
salvos (Figure 1). VT was deﬁned as a run of 4 or more consecutive
ventricular premature complex. VF was deﬁned as a ventricular
rhythmwithout a recognizable QRS complex, with changing signal
morphology from cycle to cycle. The arrhythmic periods that
included the time interval between the onset of arrhythmias and
the end of the arrhythmias were measured for the reperfusion
period and the length of arrhythmic attacts was also measured for
both periods. The incidences of VF, VT, other types of arrhythmias,
and mortality were quantiﬁed for the reperfusion period. An
arrhythmia score was used to indicate the severity of arrhythmias
based on the type and duration of arrhythmic episodes by giving
a grade to each animal as follows: 0 ¼ no arrhythmia; 1 ¼
≤10 seconds VT and/or other types of arrhythmias, no VF; 2 ¼ 11 to
30 seconds VT and/or other types of arrhythmias, no VF; 3 ¼ 31 to 90
seconds VT and/or other types of arrhythmias, no VF; 4 ¼ 91 to
180 seconds VT and/or other types of arrhythmias and/or
o10 seconds reversible VF; 5 ¼ ≥180 seconds VT and/or other
types of arrhythmias and/or 410 seconds reversible VF; and
6 ¼ irreversible VF.22Drug treatments and experimental groups
We obtained pure powder montelukast from Sanoﬁ Company
(Levent, İstanbul, Turkey) and purchased zileuton from Sigma
Chemical Co (St. Louis, Missouri). Zileuton and montelukast were
dissolved in 1% dimethyl sulfoxide (DMSO) and 0.9% saline
solution, respectively. Drugs were applied in a volume of 100 μL/kg.
The doses of zileuton and montelukast and their administration
routes and timing used in this study are based on previous
studies.14–16,18 Zileuton was administrated through a femoral vein
at a dose of 1 and 3 mg/kg. Montelukast was applied IP at a dose of
10 and 30 mg/kg.
The experimental protocol consisted of 5 separate groups: Control: 100 μL/kg, IV 1% DMSO, and IP 0.9% sodium chloride,
15 minutes before coronary ligation, respectively. Zileuton: IV 1 mg/100 μL/kg zileuton and 100 μL/kg IP 0.9%
sodium chloride, 15 minutes before coronary artery ligation,
respectively. Zileuton: IV 3 mg/100 μL/kg zileuton and 100 μL/kg IP 0.9%
sodium chloride, 15 minutes before coronary artery ligation,
respectively.Table II
The effects of drug treatments on the incidence of arrhythmias during 6 minutes of
reperfusion.Montelukast: IP 10 mg/100 μL/kg montelukast and 100 μL/kg IV
1% DMSO, 15 minutes before coronary artery ligation,
respectively.Group
Dose
(mg/kg) n*
Zone at
risk (% of
total)
Mortality
n†/%
Incidence of
arrhythmias (n‡/%)
VF VT OtherMontelukast: IP 30 mg/100 μL/kg montelukast and 100 μL/kg IV
1% DMSO, 15 minutes before coronary artery ligation,
respectively.Mean [SE]
Control - 7 46 [2] 0/0 3/43 7/100 7/100
Zileuton 1 7 44 [4] 0/0 0/0 3/43 7/100
Zileuton 3 7 52 [3] 0/0 0/0 2/29§ 5/71
Montelukast 10 6 44 [1] 0/0 1/17 3/50 6/100
Montelukast 30 6 49 [2] 0/0 0/0 5/83 6/100
Other ¼ other types of arrhythmias; VF ¼ ventricular ﬁbrillation; VT ¼ ventricular
tachycardia.
nThe number of animals just before the reperfusion.
†The number of dead animals after 6 min of reperfusion.
‡The number of animals experienced arrhythmia.
§P o 0.05 compared with control.Statistical analysis
For the statistical analysis of the survival rate and the incidence
of arrhythmias, Fisher exact test was employed. The other pare-
meters were expressed as mean [SE] and all comparisons between
the control and drug treated groups were made using a 1-way
analysis of variance and Dunnett’s post hoc test. Preocclusion and
postocclusion MABP and HR values were also compared using a
1-way analysis of variance and Dunnett post hoc test. Changes
were considered signiﬁcant at P o 0.05.Results
All groups exhibited a characteristic decrease in MABP upon the
occlusion of the coronary artery (P o 0.05). MABP showed a
moderate recovery in the late phase of ischemia. However, the
MABP recovered earlier in the zileuton-treated (3 mg/kg) group
and approached the basal value during the ﬁfth. minute of ligation
in this group. Following reperfusion, MABP increased gradually
and approached the basal value observed before ligation. None of
the drug treatments had any signiﬁcant effect on HR at any time
point (Table I). The MABP, HR, and the percentage of the ischemic
risk zone was not different between the drug-treated groups and
the control group (see Table I and Table II).
The ligation of coronary arteries resulted in the generation of
arrhythmias, occurring as the other types of arrhythmias, including
single extrasystoles, bigeminy, and salvos (Figure 1). Drug treat-
ments did not affect the duration of other types of arrhythmias
during 6 minutes of ligation. Neither control nor drug-treated
groups experienced any VF and VT (data not shown).
In all groups, reperfusion-induced arrhythmias started within
0 to 20 seconds of the reperfusion period. With regard to the
incidence of VF, VT, other types of arrhythmias, and mortality, there
Table III
The effect of drug treatments on the duration of arrhythmias during 6 minutes of reperfusion.
Groups Dose (mg/kg) n
Arrhythmia
score
Arrhythmic
period (sec)
Length of arrhythmias (sec)
VF VT Other Total
Mean [SE]
Control - 7 2.9 [0.3] 133 [19] 2 [1] 35 [13] 11 [2] 48 [14]
Zileuton 1 7 1.4 [0.8]* 124 [44] 0 7 [7]* 8 [8] 16 [10]*
Zileuton 3 7 1.3 [0.5]* 34 [17]* 0 5 [2]* 3 [3]* 8 [4]*
Montelukast 10 6 1.8 [0.5] 104 [41] 1 [1] 11 [7] 9 [2] 20 [10]
Montelukast 30 6 2.0 [0.0] 101 [13] 0 10 [4] 12 [3] 22 [4]
Other ¼ other types of arrhythmias; VF ¼ ventricular ﬁbrillation; VT ¼ ventricular tachycardia.
nP o 0.05 compared with control.
E. Gonca / Current Therapeutic Research 75 (2013) 27–3230was no signiﬁcant difference among groups. Only exception was the
higher dose of zileuton group (3 mg/kg) in which the incidence of
VT signiﬁcantly decreased compared with control (Table II).
Both doses of zileuton (1 and 3 mg/kg) reduced the arrhythmia
[SE] scores, the duration of VT, and the total length of arrhythmias
during the 6 minutes of reperfusion (arrhythmia scores: zileuton
1 mg/kg, 1.4 [0.8]; zileuton 3 mg/kg, 1.3 [0.5] vs control, 2.9 [0.3];
P o 0.05) (see Table III and Figure 2). Treatment with 3 mg/kg
zileuton but not 1 mg/kg zileuton, decreased the mean [SE]
duration of arrhythmic periods and other types of arrhythmias
(length of arrhythmic period(s): zileuton 3 mg/kg 34 [17] vs
control, 133 [19]; P o 0.05) (Table III). Both doses of Montelukast
(10 and 30 mg/kg) did not signiﬁcantly decrease the duration of
any type of arrhythmias (see Table III and Figure 3).Discussion
Because leukotriene production increases in patients with
cardiac ischemia,9 we assumed that the inhibition of LTs would
suppress ventricular arrhythmias following ischemia and reperfusion.
Although zileuton, a 5-LO inhibitor, and montelukast, a Cys-LT
receptor antagonist, are currently in use as effective antiasthma
agents,11 their potential clinical usefulness in preventing reperfusion-
induced arrhythmias has not been clariﬁed.
My study demonstrated that zileuton pretreatment at doses of
1 and 3 mg/kg suppressed reperfusion-induced arrhythmias in an
in vivo anesthetized rat model. To the best of our knowledge, this
is the ﬁrst report of the effect of zileuton on reperfusion-induced
ventricular arrhythmias. This ﬁnding is in line with the results of a**
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Figure 2. The effect of drug treatments on the arrhythmia score during 6 minutes
of reperfusion. Values are means [SD]. *P o 0.05 compared with control.recent clinical study23 in which zileuton treatment decreased the
number of tachycardia events in patients with permanent atrial
ﬁbrillation.
Zileuton has been shown to possess tissue-protective effects in
nerve and testicular tissues.12,13 This effect was suggested to be the
result of its anti-inﬂammatory and antioxidant effects. The excess
LTs produced in ischemic myocardial tissue activate neutrophils,
which promote oxidative stress and the development of intra-
cellular ionized calcium overload.24 Intracellular ionized calcium
overload and oxidative stress are considered the major factors that
lead to ventricular arrhythmias in reperfused myocardium.25,26
Therefore, in my study, zileuton may have suppressed reperfusion-
induced arrhythmias by decreasing LT production and reducing
the number of activated neutrophils, which suppressed oxidative
stress and intracellular ionized calcium overload. Likewise, the
dual inhibition of lipoxygenase (LO) and cyclooxygenase (COX) by
BW755C has been proposed to be protective against digoxin-
induced arrhythmias.27
In a recent study, another LO inhibitor, baicalein, was found to
suppress reperfusion arrhythmias in an in vivo rat coronary
ligation model.28 The results of that study suggest that reperfusion
arrhythmias originate from mitochondrial depolarization, which is
mediated by LO and reactive oxygen species release. In my study,
the antiarrhythmic effect of zileuton may also be attributed to the
inhibition of mitochondrial membrane depolarization, which is
mediated by its inhibitory action on 5-LO.
In my study, the administration of zileuton at a dose of 3 mg/kg
resulted in the earlier recovery of baseline MABP. This result
indicates that zileuton may have a protective effect on ischemic
myocardium. Likewise, it has recently been demonstrated that
zileuton protects cardiomyocytes from hydrogen peroxide-induced
cytotoxicity.29 In this study, it was suggested that pharmacologic
inhibition of 5-LO by zileuton leads a shunt from the 5-LO pathway
to COX-2 and the protective effect of zileuton was suggested to
depend on a signaling pathway that involves the induction of COX-2
mediated through the protein kinase C delta-dependent activa-
tion of extracellular-signal-regulated kinases 1/2 and protein
kinase B. In this study, zileuton may also have exhibited
a cardioprotective effect via the activation of this type of pathway.
Similarly, the protein kinase C and extracellular-signal-regulated
kinases 1/2-dependent signaling pathway may also mediate the
mitochondrial ATP-sensitive potassium channel (mitoKATP) activa-
tion,30 which has recently been demonstrated to decrease
I/R-induced arrhythmias in anesthetized rats.31 Therefore, in my
study, zileuton may also have activated mitoKATP channels to
suppress arrhythmias. In previous studies, the activation of mito-
KATP channels has been shown to mediate the antiarrhythmic
effects of estrogen and oxytocin.32,33
The doses of montelukast, a higher dose (30 mg/kg) and a lower
dose (10 mg/kg) used in our study have previously been reported
Control
Zileu 1 mg *
*Zileu 3 mg
Monte 10 mg
Monte 30 mg
0 10 20 30
Second
VF
VT
Other
40 50 60
Figure 3. The effect of drug treatments on the total length of arrhythmias during
6 minutes of reperfusion. Values represent means [SE]. Other ¼ other types of
arrhythmias; VF ¼ ventricular ﬁbrillation; VT ¼ ventricular tachycardia. *P o 0.05
compared with control.
E. Gonca / Current Therapeutic Research 75 (2013) 27–32 31to decrease myocardial injury in the rat model of isoproterenol-
induced necrosis.18 Altough we found that neither dose of mon-
telukast was effective in preventing I/R-induced arrhythmias, it
nonsigniﬁcantly decreased the duration of VT and the total length
of arrhythmias during the reperfusion. The doses of montelukast
higher than 30 mg/kg might be effective against I/R-induced
arrhythmias.
The different effects of zileuton and montelukast treatments
can be explained by the different action mechanisms of these
compounds. Zileuton inhibits the production of both LTB4 and
Cys-LTs by inhibiting the 5-LO enzyme, whereas montelukast
antagonizes the effects of Cys-LTs (LTD4 and the secondary ligands
LTC4 and LTE4) by selectively blocking the Cys-LT1 receptor on
target cells.34 These results suggest that metabolites of 5-LO
(especially LTB4) may contribute to I/R-induced arrhythmias. The
effectiveness of montelukast may also indicate that the underlying
antiarrhythmic effect of zileuton is dependent on possible non-
speciﬁc effects, such as protein kinase C activation and the
inhibition of mitochondrial depolarization, rather than the LT
pathway.Limitations
Further studies are needed to examine if treatment with
zileuton immediately postischemia, but before reperfusion, is
effective against I/R-induced arrhythmias to test applicability of
these results to human beings.Conclusions
My study clearly demonstrated for the ﬁrst time that zileuton
suppresses reperfusion-induced arrhythmias. Zileuton, which is
currently used for the treatment of asthma, may also be a
candidate for the treatment of reperfusion-induced arrhythmias.
However, further studies should be conducted to determine the
mechanism underlying its antiarrhythmic activity and to inves-
tigate the applicability of these results to human beings.Acknowledgments
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